EyePoint Pharmaceuticals, Inc.

How big is EyePoint Pharmaceuticals, Inc.?

As of Jun 18, EyePoint Pharmaceuticals, Inc. has a market capitalization of 606.23 million, with net sales of 56.04 million and a net profit of -146.79 million over the last four quarters. The company's balance sheet shows shareholder's funds of 336.50 million and total assets of 418.46 million.

As of Jun 18, EyePoint Pharmaceuticals, Inc. has a market capitalization of 606.23 million, categorizing it as a Micro Cap company.<BR><BR>As of the latest four quarters, EyePoint Pharmaceuticals reported net sales of 56.04 million and a net profit of -146.79 million.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of 336.50 million and total assets of 418.46 million.

What does EyePoint Pharmaceuticals, Inc. do?

EyePoint Pharmaceuticals, Inc. develops drug delivery products for chronic eye diseases and has a market cap of $606.23 million. As of March 2025, it reported net sales of $24 million and a net loss of $45 million.

Overview: <BR>EyePoint Pharmaceuticals, Inc. develops drug delivery products primarily for the treatment of chronic eye diseases and operates within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 24 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -45 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 606.23 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.06 <BR>Return on Equity: -49.19% <BR>Price to Book: 2.03<BR><BR>Contact Details: <BR>Address: 480 Pleasant St Ste B300, WATERTOWN MA: 02472-2468 <BR>Tel: ['1 617 9265000', '1 617 3406075'] <BR>Fax: 1 617 9265050 <BR>Website: https://eyepointpharma.com/

Should I buy, sell or hold EyePoint Pharmaceuticals, Inc.?

Who are in the management team of EyePoint Pharmaceuticals, Inc.?

As of March 2022, the management team of EyePoint Pharmaceuticals, Inc. includes Dr. Goran Ando (Independent Chairman), Nancy Lurker (CEO), and several directors: Wendy DiCicco, Ye Liu, Ronald Eastman, Douglas Godshall, and David Guyer. They oversee the company's strategic direction and operations.

As of March 2022, the management team of EyePoint Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Dr. Goran Ando, Independent Chairman of the Board<BR>- Ms. Nancy Lurker, President, Chief Executive Officer, Director<BR>- Ms. Wendy DiCicco, Director<BR>- Mr. Ye Liu, Director<BR>- Mr. Ronald Eastman, Independent Director<BR>- Mr. Douglas Godshall, Independent Director<BR>- Dr. David Guyer, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is EyePoint Pharmaceuticals, Inc. technically bullish or bearish?

As of August 26, 2025, EyePoint Pharmaceuticals, Inc. shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite a bearish monthly KST, and has significantly outperformed the S&P 500 with a year-to-date return of 84.70%.

As of 26 August 2025, the technical trend for EyePoint Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, supporting the positive stance. Daily moving averages also indicate a bullish trend. However, the monthly KST is bearish, which presents a mixed signal. The Dow Theory shows mildly bullish conditions on both weekly and monthly time frames. <BR><BR>In terms of performance, EyePoint has outperformed the S&P 500 across multiple periods, with a year-to-date return of 84.70% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish with moderate strength, driven primarily by the bullish MACD and Bollinger Bands.